
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc. is focused on the development of innovative gene therapies for neurodegenerative diseases, specifically through their pipeline candidate PBFT02, which aims to address critical underlying pathologies. The company's management anticipates that an amended trial protocol may enable earlier intervention in the disease process, potentially enhancing the benefits derived from PBFT02, while also expediting trial timelines through the parallel enrollment of Cohort 3. Additionally, the opportunity for regulatory alignment on accelerated approval based solely on biomarker endpoints could significantly shorten those timelines, positioning Passage Bio favorably against competitors in the genetic medicine landscape.
Bears say
Passage Bio Inc faces significant challenges that contribute to a negative outlook on its stock, primarily related to clinical and manufacturing risks. The company is developing early-stage gene therapies, and any delays in clinical timelines or the emergence of safety concerns, such as immune reactions, could severely impact market sentiment and lead to downward revisions of financial forecasts. Additionally, the complexity of manufacturing AAV-based gene therapies may result in further delays in product development and commercialization, complicating the path to regulatory approval and hampering the company's growth prospects.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares